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Aim of study: To investigate the inhibitory effect of Coptidis rhizome aqueous extract (CRAE) 
on vascular endothelial growth factor (VEGF) expression and tumour angiogenesis in 
hepatocellular carcinoma (HCC). Methods: Quality control of CRAE was determined. Secretion 
of VEGF protein and expression of its mRNA in MHCC97L and Hep G2 cells were measured 
with enzyme-linked immunosorbent assay and quantitative real time-polymerase chain reaction. 
Synthesis of nascent protein was determined by AHA-protein labelling technologies. The in vivo 
anti-angiogenic effect of CRAE was evaluated with xenograft model. Results: Absence of 
organochlorine pesticides in CRAE was found and phytochemical analysis showed that its 
components were in proportion of magnoflorine 2.2%, jatrorrhizine 1.68%, palmatine 4.4% and 
berberine 13.8%. CRAE exhibited significant inhibition on VEGF secretion from MHCC97L 
and HepG2 cells at non-toxic doses. The mRNA transcripts of VEGF could not be inhibited by 
CRAE, however, synthesis of VEGF nascent protein was potently blocked by CRAE. CARE 
intervention increased the phosphorylation of eukaryotic elongation factor 2 (eEF2) in HCC cells, 
which blocked eEF2 activity for proceeding nascent protein synthesis. The activity of eEF2 was 
restored in CRAE-treated HCC cells in the presence of A484594, leading to the  recovery of 
VEGF expression. Berberine was found to be the major active component in CRAE, however, 
CRAE is more effective in inhibiting eEF2 activity compared to berberine treatment alone, 
suggesting the additive effect of other components present. Reduction of tumour size and 
neovascularization were observed in mice xenograft model. Conclusion: Our study postulates 
the anti-angiogenic effect of CRAE on hepatocellular carcinoma via eEF2 driven pathway.  
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Liver cancer is the seventh most common cancer and third most cancer-related mortality for both 
genders in the world, causing about 700,000 deaths annually
1
. Hepatocellular carcinoma (HCC) 
is the most prevalent type of death leading liver cancer, with only 15% 5-year survival rate of 
liver cancer patient
2
. The major complications of HCC re ineffectiveness of existing drug against 
HCC, lack of biomarker to diagnose the disease in early and recurrence stages and other 
underlying liver diseases such as cirrhosis and liver fibrosis
3
, which all make the treatment 
become difficult. Even in HCC patients suitable for surgical reception, invasiveness and 
aggressive metastatic spread of HCC cells have rendered tumor recurrence after resection
4
. 
Evidences have showed detachment and spread of tumor cells from one location to another 
requires formation of new blood vessels
5-6
, the process was termed as angiogenesis. The loose 
and irregular structure of new blood vessels  allows tumor cells to infiltrate in and migrate to 
distinct organs.  Vascular endothelial growth factor (VEGF) is the most studied angiogenic 
factor which has a dominant role in responding the proliferation of endothelial cells and vascular 
permeability
7
.   
Coptidis rhizome (Huang Lian in Chinese) has been well-reviewed thousands of years ago in 
Shen Nong’s Herbal Classic for its effect in reducing damp-heat, fire, and toxicity in the human 
body. It is also used for treatment of diarrhea, eyes inflammation and abdomen pains of 
females
8-9
. Accumulating studies reported pharmacological benefits of Coptidis rhizome and its 
major component berberine on kidney injury improvement, inflammation prevention, cell 
growth arrest, autophagic cell death, chemoprevention, hepatoprotective and improvement in 
insulin resistance
10-16
. Studies have also demonstrated  down-regulation of secretory protein and 
transcriptional level of VEGF by berberine. This was associated with the activation of ERK and 
suppression of MMP2 that affected VEGF-induced proliferation of endothelial cells
17-18
. 
Another study showed the inhibitory effect of berberine on endothelial cells tube formation 
through degradation of HIF-1α protein, a transcriptional factor expressed during oxygen 
depletion
19
. In recent years, Coptidis rhizome has been reported to actively suppress cancer 




 and breast cancer
22
. Our previous study 
demonstrated anti-invasive effect of CRAE in HCC cells via deregulation of F-actin and 
Rho/ROCK signalling pathway
23
. Up-regulation of miR23a and miR21 that associated with 
tumour suppression has also reported on CRAE intervened HCC cells
24
. The hepatoprotective 
action of CRAE has been also addressed, which suggest its benefit to the liver organs
25-26
. 
































































However, whether Coptidis rhizome could suppress tumour angiogenesis of HCC remains 
unclear. The underlying mechanism also request further elaboration.. 
In this study, we targeted on VEGF to examine the effect of Coptidis rhizome on tumour 
angiogenesis of HCC. We observed the toxicity of Coptidis rhizome aqueous extract on 
MHCC97L and Hep G2 cells and reduction on subcutaneous growth of MHCC97L tumour size 
in animal model. The effect of Coptidis rhizome aqueous extract in attenuating secretion of 
VEGF was associated with inhibition of eEF2 and blockade of nascent protein synthesis. We 
also proposed the additive effect of other compounds other than berberine in  CRAE that 
contribute to the activity. These findings have unravelled the new molecular mechanism of 
regulating VEGF expression at post-transcriptional level by Coptidis rhizome and berberine on 
hepatocellular carcinoma.  
 
Methods  
Chemicals and Reagents 
Organochlorine pesticides (OCPs), berberine, palmatine and 3-(4,5-Dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT) were purchased from Sigma-Aldrich (USA). Jatrorrhizine 
was purchased from NICPBP (China) and magnoflorine from Tauto Biotech (China). Rabbit 
monoclonal antibodies against GADPH, eEF2 and peEF2 were purchased from Cell Signalling 
Technologies (USA); and α-tubulin from AbCam (UK). Rabbit polyclonal antibody was 
purchased from Santa Cruz (USA). 
 
Sample preparation 
The dried rhizome of Coptis chinensis Franch species (Ranunculaceae) was collected from 
Sichuan, China. The collected Coptidis rhizome crude herb was washed, dried and cut into small 
pieces. 100g of herb was boiled in 1L of distilled water at 100
0
C for 1 hour. The crude extracts 
were filtered and evaporated in vacuo using rotary evaporator. The dried concentrated crude 
extract was stored in -20
0
C freezer.    
 
Phytochemical Analysis 
To determine the presence of organochlorine pesticide in  CRAE, the sample was subjected to 
gas chromatography analysis. Determination was performed on Agilent 6890 N gas 
chromatography system equipped with 5973 Network mass selective detectors and HP-5MS 
30m x 0.25mm x 0.25µm column (Agilent Technologies). CRAE was developed in condition of 
































































50˚C for 3 min; 50 ˚C- 100 ˚C at 20 ˚C/min; 100 ˚C- 210 ˚C at 10 ˚C/min; 210 ˚C- 250 ˚C at 8 
˚C/min; 250 ˚C  for 4 min in helium carrier gas flow rate of 1 mL/min. The profile for 
organochloride pesticides (OCPs) standards was previously optimized and developed.  
 
CRAE was subjected to high performance liquid chromatography for fingerprinting analysis. 
The separation was performed using Waters model HPLC instrument, equipped with 626 pumps 
controlled by 600s interface module and a photodiode array detector 996. 10µl of CRAE 
(0.5mg/mL) was injected and eluted on ACE 5 aqueous column (250mm x 4.6mm i. d.) with 
mobile phase of 0.05M potassium dihydrogen phosphate-HPLC graded acetonitrile (75:25). The 
flow rate was 1mL/min. Berberine, jatrorrhizine, palmatine and magnoflorine (0.05mg/mL) were 
dissolved in methanol and injected as standard markers.  
 
Cell lines and Cell culture 
Two human hepatocellular carcinoma cell lines, Hep G2 and MHCC97L were chosen for the 
following experiment. Hep G2 was purchased from ATCC while MHCC97L was a gift by Dr. 
Man Kwan in Department of Surgery, The University of Hong Kong. Both cell lines were 
maintained in DMEM medium with 10% FBS and 1% penicillin/streptomycin. The cells were 
cultured in tissue culture flasks and maintained in humidified incubator at 37
0
C with 5% CO2. 
  
Cell Viability Assay 
Cell viability of Hep G2 and MHCC97L were determined by MTT assay based on the protocols 
described by Mosmann
27
. Both cells (7.0 x 10
4
cells/mL) were treated with CRAE in serial 
concentrations (512, 256, 128, 64, 32, 16, and 8µg/mL) and incubated for 24 and 48 hours. 10µL 
of 5mg/mL MTT (3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyl tetrazolium bromide) (Sigma-
Aldrich, USA) solution was added to each well. After 4 hours of incubation, the supernatant was 
removed and 100µL of DMSO was added to dissolve the remaining formazan crystal. The 
absorbance was measured at wavelength of 550nm by Multiskan MS microplate reader 
(Labsystems, Finland). 
 
VEGF Enzyme-linked Immunosorbent assay (ELISA) 
Secretion of VEGF was measured by Human VEGF ELISA kit (ExCell Biology, Shanghai) 
according to the manufacturer’s protocol. Briefly, the culture supernatant was incubated with 
biotinylated antibody on anti-VEGF monoclonal antibody pre-coated 96 wells plate for 1 hour. 
The wells were washed and HRP-conjugated streptavidin was added to all wells for 30 minutes 
































































of incubation. The plate was washed and TMB substrate solution was added to each well for 
another 30 minutes. Lastly, stop solution was added to each well before absorbance 
determination at 450 nm using Multiskan MS microplate reader (Labsystems, Finland). The 
experiment was conducted in triplicate.  
  
Quantitative Real-time PCR 
Firstly, the total RNA was extracted using RNA isoplus reagent (Takara, Japan) according to the 
manufacturer’s protocol. Each 0.5µg of RNA sample was then reverse transcribed into cDNA 
(Reverse Transcription kit, Takara, Japan). The quantitative real-time PCR was performed by 
SYBR Premix Ex Taq (Takara, Japan) with LightCycler 480 real-time PCR system (Roche, 
USA). The primer used was VEGF 5’-CCTCCGAAACCATGAACTTT- 3’ (forward) and 5’-
TTCTTTGGTCTGCATTCACATT-3’ (reverse). Relative quantification of mRNA levels was 
normalised using β-actin as the endogenous control. 
 
Immunoblotting 
The cell pellets were lysed with RIPA buffer supplemented with proteinase inhibitor (1% PMSF, 
0.5% apotinin and 0.5% leupitine) and phosphatase inhibitor (1mM Na3VO4 and 1mM NaF) 
and protein concentration was determined using BSA as standard. 10µg of protein sample was 
resolved by 10% sodium dodecyl-sulphate acrylamide gel and transferred to polyvinylidene 
difluoride membrane (Biorad, USA). The membrane was blocked with 5% BSA and probed with 
antibodies to α-tubulin, GADPH, eEF2 and peEF2 overnight. The membrane was then incubated 
with HRP-conjugated rabbit antibody before visualised with ECL Advanced kit (GE Healthcare, 
UK) by chemiluminescence imaging system (Biorad, USA). 
 
Nascent protein synthesis 
To label CRAE-treated Hep G2 and MHCC97L cells with Click-iT L-azidohomoalanine (AHA), 
the pre-treated cells were cultured in methionine free medium overnight. 30µM of AHA was 
added to the cells followed by four hours of incubation. The nascent proteins were extracted with 
Click-iT Protein reaction buffer kit (Invitrogen, UK).  
 
Xenograft Model 
A xenograft tumour model was established in nude mice by subcutaneously injecting 1×10
6 
MHCC97L cells/ml into the right flank of the mice. The tumours were allowed to grow for 
seven days. CRAE (50 mg/kg/two days, i.p for three weeks) treatment was initiated on one 
































































group of mice (n=5), and another group (n=5) was subjected with the same volume of PBS as 
control. The mice were sacrificed after three weeks with intraperitoneal injection of overdose 
pentobarbital (200mg/kg); tumours were then removed and measured. The animal experimental 
protocol has obtained the approval from the Committee on the Use of Live Animal in Teaching 
and Research (CULATR) in The University of Hong Kong. After that, the tumours were 
subjected to immunohistochemistry staining to evaluate multi vessel density and cellular 
proliferation of tumour cells with rat monoclonal antibody CD31 and Ki67 (AbCam).  
 
Results 
Quality assessment of CRAE via GC-MS and HPLC 
Comprehensive quality assessment was conducted to ensure the consistency and safety of the 
components in this herbal extract. In order to determine any presence of organochlorine 
pesticides in CRAE, it was subjected to GC-MS and analysed under optimised chromatographic 
condition. The CRAE chemical profile was further compared to the previously obtained 
fingerprint profile of OCP standards and there was no peak detected in CRAE (Supplementary 
data). CRAE was subjected to HPLC analysis to confirm its quality before treatment. The HPLC 
fingerprint profile of CRAE was compared to the four external standard profiles based on its 
retention time and UV spectrum. The yield of four constituents was calculated and as follows: 
magnoflorine 2.2%, jatrorrhizine 1.68%, palmatine 4.4% and berberine 13.8% (Figure 1). 
 
Expression of VEGF was blocked by CRAE at non-toxic doses 
To evaluate the effect of CRAE on the expression of VEGF in HCC cells, we first of all 
evaluated the toxicity of the extract to HCC cell lines, Hep G2 and MHCC97L. The cytotoxicity 
of CRAE-treated MHCC97L and Hep G2 cells were determined after 24 hours and 48 hours of 
incubation. CRAE exerted 50% of cytotoxicity against MHCC97L at the dose of 500µg/mL and 
150µg/mL  at 24 hours and 48 hours (Figure 2A). As to Hep G2 cells, 50% of cell death was 
observed after treatment with 250µg/mL and 120µg/mL of CRAE at 24 hours and 48 hours, 
respectively (Figure 2B). Based on the obtained results, the non-toxic dose of 75µg/mL and 
150µg/mL of CRAE were employed for further experiments. MHCC97L and HepG2 cells were 
then subjected to ELISA after exposure to CRAE for 24 hours. Results showed more than 2-fold 
of secretory VEGF protein reduction in both cell lines compared to control (Figure 2C). These 
results indicated that extract of Coptidis rhizome could inhibit the VEGF expression, which is 
independent to its cytotoxicity. 
 




































































has reported that berberine, the component in CRAE, could suppress the 
expression of VEGF in transcriptional regulatory manner. Therefore, we further examined if 
CRAE could have the same effect on VEGF transcripts. The mRNA level of VEGF in CRAE-
treated HCC cells was determined by quantitative real-time PCR. Unexpectedly, no significant 
reduction of VEGF mRNA transcripts was observed in HCC cells after CRAE treatment. Instead, 
the amounts of VEGF mRNA increased three-fold in CRAE-treated cells (Figure 2D). The result 
suggested that CRAE did not affect VEGF in transcriptional level while actively attenuated 
VEGF protein secretion. To further test the post-transcriptional effect of CRAE on VEGF, we 
carried out nascent protein synthesis on CRAE-treated HCC. The CRAE-treated cells were 
incubated with L-azidohomoalanine (AHA) in methionine-free medium for four hours. The 
AHA-incorporating nascent proteins were labelled with biotin-azide and further subjected to 
immunoblotting with streptavidin-HRP as secondary antibody. Pre-treatment of CRAE on both 
cell lines blocked global cellular protein synthesis (Figure 3A). The result indicated the 
involvement of CRAE in attenuating nascent protein translation in hepatocellular carcinoma. 
 
Inhibition of VEGF nascent protein synthesis by CRAE was associated with eEF2 
inactivation 
We observed CRAE induced eEF2 phosphorylation in HCC cells, in which eEF2 was 
responsible for elongation process of cap-dependent translation. Western blot analysis showed 
phosphorylation of eEF2 in CRAE-treated MHCC97L and Hep G2 cells, suggesting the 
inactivation of eEF2 by CRAE (Figure 3B). This may indicate that blockade of VEGF nascent 
protein synthesis was associated with eEF2 inactivation in CRAE-treated HCC cells. To further 
confirm eEF2 phosphorylation by CRAE, HCC was incubated with or without eEF2k inhibitor, 
A-484954 (50µM) together with CRAE for 24 hours. Incubation of HCC with A-484954 
neutralized the expression of eEF2 (Figure 4A) and normalised the secretion of VEGF (Figure 
4B), suggesting CRAE attenuated eEF2-driven VEGF protein synthesis. Amounts of VEGF 
mRNA were increased in the presence of A-484954 and this correlated with the results obtained 
earlier, indicating CRAE has no inhibitory effect on VEGF mRNA (Figure 4C). Taken together, 




































































Berberine was the major active component of CRAE in inducing eEF2 phosphorylation 
To further elucidate the responsible constituent in CRAE that contribute to eEF2 
phosphorylation, we incubated HCC cells with individual compounds (i) Jatrorrhizine 
(2.52µg/mL) (ii) Berberine (20.7µg/mL) (iii) Palmatine (6.6µg/mL) for 24 hours. The 
compounds concentration was prepared based on its individual proportion present in CRAE. Cell 
lysates were then subjected for eEF2 phosphorylation. Western blot analysis showed berberine 
and mixture of four constituents were expressed at the same level in both cells, while berberine 
was the most active among them. However, higher expression level of phosphorylated-eEF2 was 
observed in CRAE, postulating that other constituents present in CRAE may contribute to the 
activity (Figure 5). 
 
CRAE reduced tumour size and neovascularization in xenograft HCC model  
To investigate the effect of CRAE on tumour growth in vivo, the MHCC97L xenograft mice 
were administrated with CRAE (50mg/kg/two days, i.p.) for three weeks. After 3 weeks of 
CRAE administration, the body weight of mice remain unchanged (results not shown), 
indicating CRAE has minimal toxicity to the animal at this dose. A significant reduction in 
tumour size was speculated in CRAE-treated mice in comparison to control (Figure 6A). The 
excised tumours were then measured. The tumour volumes of untreated and CRAE-treated mice 
were 1306.67 ± 100.7 mm
3 
and 656.67 ± 485.2 mm
3
. Approximately two-fold of size reduction 
was observed in CRAE-treated mice (Figure 6B). Multi vessel density and cellular proliferation 
was examined by haematoxylin and eosin staining on anti-CD31 and anti-Ki67 antibody. 
Histologic analysis against Ki-67 antibody showed a marked decrease in area of proliferating 
cells in CRAE-treated mice compared to control. Presence of CD31-postive cells was also 
apparently deceased in CRAE-treated mice (Figure 6C), indicating the reduced rate of new blood 
vessel formation. Compared to control group, CRAE-treated mice showed lower vascular 
density in tumour. 
 
Discussion  
The in vitro study has demonstrated that CRAE offsets VEGF secretion in HCC cells; however, 
it is not associated with down regulation of VEGF mRNA. Significant increase of VEGF mRNA 
after treatment may be the stabilization effect of hypoxia induced factor-1 alpha transcriptional 
factor (HIF-1α) in tumour cells
28
. In our study, we surprisingly observed that the expression of 
VEGF could be inhibited by CRAE under normoxic condition, in which HIF-1α should not be 
































































present, indicating the CRAE-suppressed VEGF is mediated through HIF-1α -independent 
mechanism. This responsible effect was further justified where we found that CRAE has no 
inhibition on mRNA transcripts of VEGF, which may rule out the presence of transcriptional 
control in VEGF regulation by CRAE.  
We reported for the first time that CRAE could suppress the synthesis of nascent protein, which 
was translated on decoded ribosomes; the unfolded and extended chain of nascent protein was 
transported through translocon into endoplasmic reticulum for further folding. VEGF is a 
glycoprotein that synthesized inside ER and ER stress could trigger VEGF up-regulation 
transcriptionally and post-translationally
29
. Our observation showed reduction of nascent protein 
synthesis after treatment with CRAE in dose-dependent manner. Consistent with these findings, 
CRAE triggered eEF2 phosphorylation was followed by blockade of nascent protein synthesis, 
leading to the inhibitory effects of VEGF protein secretion. Eukaryotic elongation factor-2 
(eEF2) is responsible on mediating ribosomal transfer in elongation process of mRNA 
translation. eEF2 is inactivated by being phosphorylated at its S56 site, which leads to disruption 
in protein synthesis
30
. Overexpression and hyperactivity of eEF2 in cancer is associated with 
cancer cell progression and early tumour recurrence
31-32
, and high level of protein synthesis is 
vital to maintain cancer cell metabolism
33
. Treatment with doxorubicin has reported to 
phosphorylate eEF2 through interfering anti-apoptotic protein and promote cancer cell death
34
. 
Previous report has postulated a novel energy-conserved mechanism where translational arrest 
caused by eEF2 phosphorylation in HIF-independent oxygen depletion condition 
35
. 
Interestingly, in our study, we discovered eEF2 phosphorylation by CRAE in dose dependent 
manner and it has been further justified through inhibition by A-484954. This suggested that 
CRAE may cause HCC to enter an energy saving mechanism that rendered post-transcriptional 
arrest and halted the production of other growth and angiogenic factors, such as VEGF. Protein 
synthesis is an ATP-exhaustive process and termination of mRNA translation turns out to be a 
tumour cell survival strategy
36
. Besides, elevation of VEGF protein in MHCC97L after A-
484954 addition was observed, suggesting post-transcriptional inhibitor may initiate cell 
compensation pathway to produce more VEGF protein. Our assumption was further supported 
by previous studies, which also reported that VEGF inhibition may trigger cell survival 
adaptations to increase VEGF protein expression and receptor activity 
37, 38
.The in vivo 
subcutaneous animal model showed a reduction of CD31 stained blood vessels and shrinkage of 
tumour size after treatment with CRAE. Data obtained has signified inhibition of tumour 
angiogenesis was involved in the anti-cancer effect of CRAE in HCC. The regulatory scheme 
































































underlying the inhibitory effect of CRAE on VEGF expression in HCC cells was showed in 
Figure 7.  
Our previous study has addressed the greater potential of Coptidis rhizome compared to 
treatment by berberine alone and the effect was contributed by other protoberberine-type 
alkaloids present in Coptidis rhizome
23
. Consistent with previous study, we observed higher 
level of eEF2 phosphorylation in CRAE, suggesting other compounds may be responsible on the 
activity but berberine was the most effective one. The current data indicated the additive effect 
of other constituents present in Coptidis rhizome.  
 
Conclusion 
In conclusion, we have elucidated the inhibition of VEGF protein synthesis by CRAE via eEF2 
driven pathway. CRAE blocked nascent protein synthesis and thereby inhibited VEGF protein 
formation. CRAE exhibits more potent inhibition on eEF2 activity than berberine alone; 
suggesting the presence of other compounds in Coptidis rhizome may contributes additive effect 
of eEF2 inactivation. This study postulated CRAE as a potential anti-angiogenic substance for 
hepatocellular carcinoma.  
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Figure 1. Chemical Analysis of CRAE with other standard references by HPLC. (A) 
Coptidis rhizome aqueous extract. (B) Magnoflorine reference standard. (C) Jatrorrhizine 
reference standard. (D) Palmatine reference standard. (E) Berberine reference standard. 
Figure 2. CRAE induced cytotoxicity and blocked VEGF expression. (A) MHCC97L cells.  
(B) Hep G2 cells were treated with CRAE at dose and time dependent manner. The cells were 
seeded to 96-wells plate and cell viability was determined by MTT assay. Cell viability were 
measured as average % of replicates (n=3) with standard deviation. (C) Amount of secretory 
VEGF of MHCC97L and Hep G2 cells. Approximately 2-fold of reduction in VEGF 
concentration was observed. The VEGF concentration was measured in average of ng/nL ± SD. 
(D) Fold change of VEGF mRNA level in HCC cells. Threefold increase of VEGF mRNA was 
observed in CRAE-treated cells versus control. The VEGF mRNA was measured in fold change 
± SD. 
Figure 3. CRAE induced blockade of nascent protein synthesis and phosphorylation of 
eEF2 in HCC cells. (A) Nascent protein synthesis in MHCC97L and Hep G2 cells was inhibited 
by CRAE. (B) MHCC97L and Hep G2 cells were treated with CRAE (0, 75, 150µg/mL). The 
lysates were immuno-blotted against anti-peEF2, anti-eEF2, and α-tubulin. Up-regulated 
expression of peEF2 was observed after treatment with CRAE.  
Figure 4. A-484954 normalised the phosphorylation of eEF2 in HCC cells. (A) MHCC97L 
and Hep G2 cells were treated with CRAE (0, 75, 150µg/mL) in presence or absence of A-
484954 (B) The secretion level of VEGF were normalised after treatment with A-484954 in 
HCC cells. The VEGF concentration was measured in average of ng/nL ± SD. (B) Level of 
VEGF mRNA increased in A-484954 pre-treated HCC cells. The VEGF mRNA was measured 
in fold change ± SD.  
Figure 5. Berberine is the major active compound in eEF2 phosphorylation. HCC cells were 
treated with Jatrorrhizine (Jat), Berberine (Ber), Palmatine (Pal), CRAE and mixture of 
compounds (mix) and analysed for peEF2 and eEF2.  
Figure 6. CRAE reduced tumour size and neovascularization in HCC xenograft model. (A) 
CRAE treated mice has decreased tumour volume compared with the untreated mice. Two 
groups of mice were treated with or without CRAE for three weeks (n=5). (B) The excised 
tumours were measured and established in average of mm
3 
± SD. Significant reduction of tumor 
volume was observed in CRAE treated mice. (C) Histological sections of HCC tumors in two 
groups of mice.  Decreased expression of Ki67 (magnification of 200x) and CD31 (low 
magnification, bar = 20µm) was observed. Lesser blood micro vessels were detected in CRAE-
treated section. Blood vessels of control section were indicated in arrows. The expression was 
measured in average of %
 
± SD. 
Figure 7. The schematic mechanism of eEF2 driven VEGF protein suppression. CRAE 
inactivates eEF2 through phosphorylation and elongation phase of mRNA translation is 
inhibited. The blockade of nascent protein synthesis leads to VEGF protein suppression.  



































































Figure 1. Chemical Analysis of CRAE with other standard references by HPLC. (A) Coptidis rhizoma aqueous 
extract. (B) Magnoflorine reference standard. (C) Jatrorrhizine reference standard. (D) Palmatine reference 
standard. (E) Berberine reference standard.  
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Figure 2. CRAE induced cytotoxicity and blocked VEGF expression. (A) MHCC97L cells.  (B) Hep G2 cells 
were treated with CRAE at dose and time dependent manner. The cells were seeded to 96-wells plate and 
cell viability was determined by MTT assay. Cell viability were measured as average % of replicates (n=3) 
with standard deviation. (C) Amount of secretory VEGF of MHCC97L and Hep G2 cells. Approximately 2-fold 
of reduction in VEGF concentration was observed. The VEGF concentration was measured in average of ng/nl 
± SD. (D) Fold change of VEGF mRNA level in HCC cells. Threefold increase of VEGF mRNA was observed in 
CRAE-treated cells versus control. The VEGF mRNA was measured in fold change ± SD.  
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Figure 3. CRAE induced blockade of nascent protein synthesis and phosphorylation of eEF2 in HCC cells. (A) 
Nascent protein synthesis in MHCC97L and Hep G2 cells was inhibited by CRAE. (B) MHCC97L and Hep G2 
cells were treated with CRAE (0, 75, 150µg/mL). The lysates were immuno-blotted against anti-peEF2, anti-
eEF2, and α-tubulin. Up-regulated expression of peEF2 was observed after treatment with CRAE.  
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Figure 4. A-484954 normalised the phosphorylation of eEF2 in HCC cells. (A) MHCC97L and Hep G2 cells 
were treated with CRAE (0µg/ml, 75µg/ml, 150µg/ml) in presence or absence of A-484954 (B) The secretion 
level of VEGF were normalised after treatment with A-484954 in HCC cells. The VEGF concentration was 
measured in average of ng/nl ± SD. (B) Level of VEGF mRNA increased in A-484954 pre-treated HCC cells. 
The VEGF mRNA was measured in fold change ± SD.  
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Figure 6. CRAE reduced tumour size and neovascularization in HCC xenograft model. (A) CRAE treated mice 
has decreased tumour volume compared with the untreated mice. Two groups of mice were treated with or 
without CRAE for three weeks (n=3). (B) The excised tumours were measured and established in average of 
mm3 ± SD. Significant reduction of tumor volume was observed in CRAE treated mice. (C) Histological 
sections of HCC tumors in two groups of mice.  Decreased expression of Ki67 (magnification of 200x) and 
CD31 (low magnification, bar = 20µm) was observed. Lesser blood micro vessels were detected in CRAE-
treated section. Blood vessels of control section were indicated in arrows. The expression was measured in 
average of % ± SD.  
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